Losartan FAERS Safety Signals: What Post-Market Surveillance Data Reveal

How FAERS Works and Why It Matters for Losartan

The FDA Adverse Event Reporting System (FAERS) is a spontaneous reporting database that collects adverse event reports from healthcare professionals, consumers, and manufacturers after a drug reaches the market. It does not prove causation, but it generates signals that trigger deeper investigation. For a drug prescribed over 50 million times per year in the United States, the volume of reports matters.

Losartan has been on the market for over three decades. That long exposure window means FAERS has accumulated a substantial body of reports. The database recorded more than 60,000 adverse event reports for losartan through Q4 2024, according to data available on the FAERS Public Dashboard. Not every report represents a drug-caused event. Many patients taking losartan are elderly, have multiple comorbidities, and use concomitant medications that independently raise the risk of renal or electrolyte adverse events.

Still, certain signal patterns recur with enough frequency and biological plausibility that the FDA has acted on them through label updates, safety communications, and, in the case of nitrosamine contamination, product recalls spanning years.

Hyperkalemia: The Most Clinically Relevant Signal

Hyperkalemia is the adverse event most tightly linked to losartan's mechanism of action, and it accounts for a disproportionate share of serious FAERS reports. By blocking angiotensin II at the AT1 receptor, losartan reduces aldosterone secretion. Less aldosterone means less potassium excretion. The result can be dangerous.

The current FDA-approved prescribing information reports that in clinical trials for diabetic nephropathy (the RENAAL study, N=1,513), the incidence of hyperkalemia (serum potassium >5.5 mEq/L) was 6.0% in the losartan group versus 3.2% in the placebo group [1]. Post-market surveillance has confirmed this signal remains active. A 2020 pharmacovigilance analysis published in Pharmacoepidemiology and Drug Safety found that ARBs as a class, including losartan, generated a reporting odds ratio (ROR) for hyperkalemia of 3.8 (95% CI: 3.5 to 4.1) in FAERS [2].

Risk multiplies when losartan is combined with potassium-sparing diuretics, potassium supplements, or other renin-angiotensin-aldosterone system (RAAS) inhibitors. The Endocrine Society and AHA guidelines recommend checking serum potassium within 1 to 2 weeks of initiating losartan or adjusting the dose, especially in patients with estimated GFR <45 mL/min/1.73m² [3].

Acute Kidney Injury and Renal-Related Events

Acute kidney injury (AKI) is the second major FAERS signal for losartan. This is a class effect of all RAAS inhibitors. Losartan dilates the efferent arteriole of the glomerulus, which reduces intraglomerular pressure. In a well-hydrated patient with normal renal perfusion, this is protective. In a volume-depleted patient, or one whose renal perfusion depends on angiotensin II (bilateral renal artery stenosis, severe heart failure, cirrhosis), the result is a drop in glomerular filtration rate that can precipitate AKI.

FAERS data show AKI reports spike in temporal association with concurrent NSAID use and diuretic therapy ("triple whammy" combination). A large Australian cohort study (N=487,372) published in the BMJ found that the combination of a RAAS inhibitor plus diuretic plus NSAID was associated with a rate ratio of 1.31 (95% CI: 1.12 to 1.53) for AKI requiring hospitalization compared with RAAS inhibitor use alone [4].

The FDA label for losartan includes language warning that "changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system." Physicians should monitor serum creatinine after initiation, particularly in patients with pre-existing renal impairment, heart failure, or volume depletion [1]. Short-term creatinine elevations of up to 30% from baseline may be tolerable and even nephroprotective in the long term, but elevations beyond that threshold warrant dose reduction or discontinuation.

Angioedema: A Rare but Serious Signal

Angioedema is far less common with ARBs than with ACE inhibitors, but it is not absent. ARBs were originally positioned as the safe alternative for patients who developed angioedema on ACE inhibitors. FAERS data complicate that narrative somewhat. A cross-reactivity rate of approximately 2% to 17% has been reported in patients who switch from an ACE inhibitor to an ARB after angioedema, depending on the study [5].

The FDA label for losartan warns that angioedema, including swelling of the larynx and glottis, has been reported in patients treated with losartan. Dr. Nancy Byatt, in a review of post-market ARB safety for the American Academy of Allergy, Asthma, and Immunology, noted: "Clinicians should not assume that angiotensin receptor blockers are completely free of angioedema risk. Patients with a history of ACE inhibitor-induced angioedema require careful monitoring if transitioned to an ARB" [5].

FAERS case reports of losartan-associated angioedema tend to cluster in Black patients, consistent with the known racial disparity in bradykinin-mediated angioedema. The mechanism may differ from ACE inhibitor angioedema (which is bradykinin-mediated) and might involve mast cell pathways, though this remains under investigation.

The Nitrosamine Impurity Crisis: 2018 to 2021

The largest regulatory event in losartan's history was not a pharmacologic safety signal at all. It was a manufacturing contamination problem. In 2018, the FDA discovered that certain generic losartan products contained N-nitrosodimethylamine (NDMA) and N-nitroso-N-methyl-4-aminobutyric acid (NMBA), probable human carcinogens, as impurities generated during synthesis [6].

The recall scope was massive. Over a three-year period, the FDA issued recalls affecting dozens of lots from manufacturers including Torrent Pharmaceuticals, Hetero Labs, Macleods Pharmaceuticals, and others. The agency estimated that patients taking the highest NDMA-contaminated losartan products daily for four years faced an additional cancer risk of approximately 1 in 8,000 above baseline [6].

Dr. Janet Woodcock, then Director of the FDA's Center for Drug Evaluation and Research (CDER), stated in a 2019 FDA update: "We want patients to know that not all ARB products were affected. We have been working to ensure that the losartan products currently on the market meet our safety standards, including acceptable levels of nitrosamine impurities" [7].

The crisis prompted systemic changes. The FDA established recommended intake limits for nitrosamine impurities across all drug products (96 ng/day for NDMA) and required manufacturers to test finished products before release. Updated guidance documents, including the FDA's 2021 guidance on nitrosamine impurities, now mandate root-cause assessments and ongoing monitoring [7].

FAERS itself saw a temporary spike in losartan adverse event reports during the recall period. Many of these were "product quality" complaints rather than clinical adverse events, reflecting public concern about impurity exposure. Distinguishing genuine pharmacologic safety signals from contamination-related quality reports remains a challenge in interpreting losartan FAERS data from 2018 to 2021.

Fetal Toxicity: The Black Box Warning

Losartan carries a black box warning for fetal toxicity. Drugs acting directly on the RAAS cause injury and death to the developing fetus when used during the second and third trimesters. Reported effects in FAERS and clinical literature include oligohydramnios, fetal renal failure, skull hypoplasia, and neonatal death [1].

The warning is unambiguous. The label states: "When pregnancy is detected, discontinue losartan as soon as possible." This is consistent across all ARBs and ACE inhibitors. FAERS data reinforce the signal, with case reports of fetal injury appearing periodically, often in patients who were not aware of their pregnancy at the time of exposure. The ACOG recommends that women of reproductive age using losartan receive counseling about contraception and the need for immediate drug discontinuation upon confirmed pregnancy [8].

Hepatotoxicity and Rarer Signals

Hepatotoxicity is an uncommon but documented FAERS signal. The NIH LiverTox database classifies losartan-associated liver injury as rare, with an estimated incidence of 1 to 10 per 100,000 users per year [9]. The pattern is typically hepatocellular or mixed, with onset ranging from 1 week to several months after initiation. Cases are generally reversible upon discontinuation.

Other lower-frequency FAERS signals include rhabdomyolysis (often in the context of concomitant statin use), taste disturbances, and cough. While cough is the hallmark adverse effect of ACE inhibitors, ARBs are not entirely free of it. The LIFE trial (N=9,193) reported cough in 2.7% of losartan-treated patients versus 0.8% of atenolol-treated patients, though this was far below the 5% to 35% rates seen with ACE inhibitors [10].

LIFE Trial and Post-Market Context

The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial remains the most consequential outcomes trial for losartan. Published in The Lancet in 2002, LIFE randomized 9,193 patients with hypertension and left ventricular hypertrophy to losartan-based or atenolol-based treatment. The losartan group demonstrated a 13% relative risk reduction in the primary composite endpoint of cardiovascular death, stroke, and myocardial infarction (adjusted p=0.021), driven primarily by a 25% reduction in fatal and non-fatal stroke [10].

LIFE also provided long-term safety data. Over a mean follow-up of 4.8 years, losartan was associated with significantly fewer cases of new-onset diabetes compared with atenolol (6% vs. 8%, p <0.001) and lower rates of discontinuation due to adverse effects [10]. These findings anchored the FDA's approval of losartan for stroke risk reduction in hypertensive patients with LVH and provided a reassuring safety profile that FAERS data have largely corroborated over the subsequent two decades.

Current Label Status and Monitoring Recommendations

The most recent FDA label revision for losartan incorporates language on nitrosamine impurity testing and maintains all prior warnings. The label specifies monitoring requirements that clinicians should follow: check blood pressure, serum potassium, and renal function within 2 to 4 weeks of initiation, after dose changes, and periodically thereafter [1].

For patients with chronic kidney disease (CKD stage 3 or higher), the KDIGO 2021 guidelines recommend tolerating up to a 30% rise in serum creatinine from baseline after RAAS inhibitor initiation, provided potassium remains <5.5 mEq/L and the patient is clinically stable [11]. Discontinuation should be considered if creatinine rises beyond 30% or potassium exceeds 5.5 mEq/L on two consecutive measurements.

Patients on losartan who develop unexplained muscle pain should have creatine kinase levels checked to evaluate for rhabdomyolysis, particularly if they are also taking statins or have renal impairment. Baseline and periodic hepatic function tests are reasonable for patients on long-term therapy, though routine screening is not mandated by current guidelines.

The recommended starting dose for hypertension is 50 mg once daily, with a maximum of 100 mg daily. For diabetic nephropathy, the target dose is 100 mg daily. Dose adjustment is required in patients with hepatic impairment (starting dose: 25 mg) and those on volume-depleting diuretics [1].